All In Biotech

Free tool

FAERS Monitor: Retevmo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213246 or its brand name (Retevmo, Selpercatinib). Reports on generic versions are filed under their own applications.

Reports

1,395

Serious

1,084

78% of reports

Hospitalization

443

Death reported

208

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • malignant neoplasm progression136
  • death114
  • diarrhoea72
  • hypertension70
  • fatigue68
  • hypersensitivity65
  • rash61
  • pyrexia50
  • hepatic function abnormal49
  • alanine aminotransferase increased42
  • aspartate aminotransferase increased42
  • off label use41
  • nausea40
  • ascites39
  • dry mouth39

Reports by year received

View as table
YearReports
202082
2021164
2022214
2023217
2024302
2025206
2026210

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,764 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
malignant neoplasm progressionSignal13620.017.12,451
ascitesSignal3920.014.7686
hepatic function abnormalSignal4919.815.1857
aspartate aminotransferase increasedSignal4211.98.9410
alanine aminotransferase increasedSignal4210.37.7345
dry mouthSignal397.35.3205
hypersensitivitySignal655.34.2223
hypertensionSignal705.04.0221
pyrexiaSignal502.21.731
rashSignal612.11.735
death1142.01.758
diarrhoea721.71.320
fatigue681.31.05
nausea400.80.63
off label use410.70.55

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.